Skip To Main Content
Rakchha Chhetri on Muck Rack

Rakchha Chhetri

As seen in: Nature, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rakchha

Contact Rakchha, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cancers | Free Full-Text | A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data

|
By Rakchha Chhetri, Kirsty Sharplin, William Proudman, Jamie Choong
| MDPI
Abstract : Simple Summary Myelodysplastic syndrome (MDS) is one of the most-common blood cancers in older individuals. Although azacitidine is the most-commonly used treatment for MDS, only 30–40% of patients respond to it, and responses may not be achieved up to six cycles of treatment. Moreover, there are no universally accepted prognostic models that will identify patients who are unlikely to benefit.
Open in Who Shared Issue with article?

The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution

|
By Deepak Singhal, Monika M. Kutyna, Rakchha Chhetri, Joel Geoghegan
| Nature Verified
Abstract Therapy-related myeloid neoplasms (T-MN) are poorly characterized secondary hematological malignancies following chemotherapy/radiotherapy exposure. We compared the clinical and mutational characteristics of T-MN (n = 129) and primary myelodysplastic syndrome (P-MDS, n = 108) patients. Although the somatic mutation frequency was similar between T-MN and P-MDS patients (93% in both groups), the pattern was distinct. TP53 mutations were more frequent in T-MN (29.5 vs.
Open in Who Shared Issue with article?
See all 2 articles